BIIB021

BIIB021 (CNF2024) is an orally active, fully synthetic inhibitor of HSP90 with a Ki and an EC50 of 1.7 nM and 38 nM, respectively[1].

Product Specifications

CAS Number

[848695-25-0]

Product Name Alternative

CNF2024

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; HSP

Type

Reference compound

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BIIB021.html

Purity

99.19

Solubility

DMSO : ≥ 45 mg/mL

Smiles

ClC1=C2C(N(C=N2)CC3=C(C(OC)=C(C=N3)C)C)=NC(N)=N1

Molecular Formula

C14H15ClN6O

Molecular Weight

318.76

Precautions

H302, H315, H319, H335

References & Citations

[1]Lundgren, Karen., et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Molecular Cancer Therapeutics (2009), 8 (4), 921-929.|[2]B?ll B, et al. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. Clin Cancer Res. 2009 Aug 15;15 (16) :5108-16.|[3]Yin X, et al. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer. 2010 Mar 1;126 (5) :1216-25|[4]Zhang H, et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer. 2010 Mar 1;126 (5) :1226-34